Boao International Medical Center
Boao International Medical Center
China, Qionghai
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
China has officially approved two disease-modifying therapies (DMTs) for spinal muscular atrophy (SMA). The National Medical Products Administration (NMPA) authorized Nusinersen (Spinraza) in February 2019 and Risdiplam (Evrysdi) in June 2021. Both drugs are included in the National Reimbursement Drug List.
Bookimed Expert Insight: While Chinese national approval exists, specialized care remains concentrated in JCI-accredited Class A level III facilities. Yanda International Hospital in Beijing serves 2,500,000 patients annually and maintains the highest clinical level. This high patient volume often leads to better-developed rehabilitation protocols after starting DMTs.
Patient Consensus: Parents frequently select Risdiplam to avoid the stress of repeated spinal injections for their children. Patients emphasize verifying if their local province has implemented the national reimbursement rates.
Zolgensma is not broadly available to patients in mainland China. While regulators granted clinical trial clearance, it lacks widespread commercial distribution. Currently, access remains restricted to specific Phase 3 clinical trial slots. Alternative therapies like nusinersen and risdiplam serve as the primary accessible options.
Bookimed Expert Insight: Patient volume at major hubs like Yanda International Hospital reaches 2,500,000 annually. Large Class A level III facilities handle most complex cases. If seeking advanced spinal care, choose doctors with international training. Dr. Siyi Cai trained at the Hospital for Special Surgery in New York. This global expertise is vital when local gene therapy access is limited.
Patient Consensus: Moving quickly is vital because the treatment window for infants closes very fast. Many families find the one-time therapy appeal is overshadowed by high costs and selective eligibility.
Accredited Class A level 3 (Grade 3A) hospitals across Beijing and Shanghai administer advanced Spinal Muscular Atrophy (SMA) therapies. These multidisciplinary centers provide nusinersen injections and risdiplam protocols. JCI-accredited facilities and university-affiliated institutions manage national patient registries and specialized intensive care units.
Bookimed Expert Insight: While many Grade 3A hospitals provide neurological care, only a few like Yanda International Hospital offer 3,000 beds. This massive capacity often correlates with faster access to multidisciplinary teams. This is crucial for SMA patients requiring coordinated respiratory and orthopedic support. For scoliosis cases, prioritize centers with image-guided lumbar puncture capabilities to ensure safe injections.
Patient Consensus: Families emphasize that securing access to specific drug pathways is harder than finding a reputable hospital. Patients suggest confirming the image-guided injection workflow before traveling to avoid scheduling delays.
Adult Spinal Muscular Atrophy patients in mainland China access the same National Reimbursement Drug List subsidies as children. Medications like Nusinersen and Risdiplam are eligible for basic medical insurance regardless of age. While drug costs are unified, adults often lose out on pediatric-specific rehabilitation grants.
Bookimed Expert Insight: While national drug lists suggest parity, hospital classification dictates actual access for adult patients. For example, Yanda International Hospital in Beijing is a Class A Level III facility that only accepts adults. Patients should target these high-level adult centers rather than pediatric institutions. These specialized clinics often have better infrastructure for the complex intrathecal injections required for adults.
Patient Consensus: Patients note that while the medicine itself is cheaper, the total cost remains a burden. They emphasize that navigating local hospital-specific rules is harder for adults than for children.
Specialized physical rehabilitation for SMA in China is not widely available nationwide. High-quality care is heavily concentrated in tier-1 cities and major provincial centers. Most patients outside these urban hubs lack access to multidisciplinary teams and consistent pediatric neuromuscular protocols.
Bookimed Expert Insight: Yanda International Hospital stands out by serving 2,500,000 patients annually as a Class A level III facility. This high patient volume suggests that major centers in Beijing offer the most robust infrastructure for long-term recovery. Patients should prioritize clinics with both JCI accreditation and dedicated neurology departments to ensure safety and protocol consistency.
Patient Consensus: Patients note that SMA rehab expertise is city-dependent and hard to find in smaller areas. Families often must create their own plans by combining hospital visits with home-based breathing and posture routines.
China reduces late Spinal Muscular Atrophy (SMA) diagnosis through maternal carrier screening, interventional prenatal diagnosis, and pilot newborn screening (NBS) programs. These methods utilize quantitative PCR (qPCR) and Multiplex Ligation-dependent Probe Amplification (MLPA) to identify SMN1 gene deletions before motor neuron damage occurs.
Bookimed Expert Insight: While China ranks 8th globally for medical requests, screening accessibility is highly concentrated in academic centers. JCI-accredited facilities like Yanda International Hospital serve millions of patients, but specialized genetic counseling is often separate. Families should prioritize hospitals with dedicated neurology departments to ensure screening leads directly to disease-modifying therapy.
Patient Consensus: Patients note that because SMA often appears without family history, parents must proactively request carrier testing. Waiting for symptoms like weakness often means missing the critical early treatment window.